A complete application in a minute
Tailored resume and cover letter, ready to send.
Das Universitätsklinikum Schleswig-Holstein sucht eine promovierte Forscherin bzw. einen promovierten Forscher im Bereich AML-Transkriptomik.
Die Stelle ist Teil des neuen Projekts LUCID-AML und zunächst auf drei Jahre angelegt, mit der Möglichkeit einer Verlängerung. Sie arbeiten eng mit compute- und klinischen Wissenschaftlern zusammen, entwickeln End-to-End-Workflows, nutzen R und Python und arbeiten an Open-Source-Tools sowie an HPC-Infrastruktur.
Das Universitätsklinikum Schleswig-Holstein (UKSH) verbindet internationale Spitzenforschung mit interdisziplinärer Krankenversorgung. Wir sind einziger Maximalversorger und größter Arbeitgeber des Landes. Unsere rund 17.500 Mitarbeitenden stellen eine höchst individuelle Versorgung sicher - unverzichtbar für die Menschen in Schleswig-Holstein.
Department of Internal Medicine II, Research Group: Functional Genomics of Acute Leukemia (Heads: Dr. Lorenz Bastian / Prof. Dr. Claudia Baldus)
The position is part of the newly established research project "LUCID-AML - Learning-based Unsupervised Clustering of transcriptomIcs to Detect developmental, functional and prognostic subtypes in AML across age", funded by the Deutsche José Carreras Leukämie-Stiftung. It is closely linked to our DFG-funded Clinical Research Unit "CATCH-ALL: Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia", where clinical and basic researchers work together to define mechanisms of leukemogenesis and treatment resistance across age groups.
Acute myeloid leukemia (AML) affects people of all ages, but its incidence increases steeply in older adults, while survival decreases sharply with age. AML can be classified into transcriptomic groups that reflect cytogenetic lesions, reveal developmental origins and link leukemias to normal hematopoietic states. However, consistent subtype definitions and robustly validated tools for applying them across cohorts are lacking.
The project builds on ALLCatchR and our work on machine-learning frameworks for disease classification and the identification of novel molecular subtypes in acute lymphoblastic leukemia. LUCID-AML will integrate more than 8,000 bulk AML gene-expression profiles from multiple cohorts with single-cell data, molecular genetics, diagnostic classifications, drug-response data and clinical outcomes. The project aims to establish reproducible, gene-expression-based AML subtypes while accounting for age and treatment. Further aims are to define their developmental origins and make the resulting models available as transparent, open-source tools for research and clinical diagnostics. For further reading: Beder et al., HemaSphere, 2023; Bastian et al., Blood, 2024; Beder et al., bioRxiv / HemaSphere, 2026.
Join our team as soon as possible. The initial appointment is for three years, with the possibility of extension.